Patient Guide: The Study of ICP-248 in Patients With Mature B-cell Malignancies

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 22 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05728658
Status: 🟢 Enrolling Now
Condition: Hematological Malignancies
Phase: PHASE1

Where You Can Participate

This study is available at 22 locations across the country.

Top locations include:
  • • Bengbu, Anhui
  • • Hefei, Anhui
  • • Beijing, Beijing Municipality
  • • And 19 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

The Study of ICP-248 in Patients With Mature B-cell Malignancies - Join Clinical Trial NCTNCT05728658

How to Join This Clinical Trial - NCTNCT05728658

Learn how to participate in this PHASE1 trial studying an investigational therapy for Hematological Malignancies. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Hematological Malignancies. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Hematological Malignancies
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05728658 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 22 locations. Find a study site near you:

Clinical Research Site

Bengbu, Anhui 233099 - China

Status: RECRUITING

Clinical Research Site

Hefei, Anhui 230022 - China

Status: RECRUITING

Clinical Research Site

Beijing, Beijing Municipality 100191 - China

Status: RECRUITING

Clinical Research Site

Chongqing, Chongqing Municipality 400016 - China

Status: RECRUITING

Clinical Research Site

Fuzhou, Fujian 350001 - China

Status: RECRUITING

Clinical Research Site

Xiamen, Fujian 361003 - China

Status: RECRUITING

Clinical Research Site

Guangzhou, Guangdong 510062 - China

Status: RECRUITING

Clinical Research Site

Zhengzhou, Henan 450008 - China

Status: RECRUITING

Clinical Research Site

Zhengzhou, Henan 450008 - China

Status: RECRUITING

Clinical Research Site

Wuhan, Hubei 430014 - China

Status: RECRUITING

And 12 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Hematological Malignancies:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships